Merck opens €300m South Korea plant for regional biopharmaMembers
The 44,500-square-meter Daejeon facility produces dry cell culture media and process liquids to cut lead times for contract…
Company watch
All companies →Samsung Biologics
Every EAB briefing that touches Samsung Biologics — capital spending, plants, M&A, earnings and policy exposure. 3 briefings.
- First seen
- September 27, 2026
- Latest
- November 1, 2026
- With a linked document
- 3 of 3
- Subject of the briefing
- 3
- Desks
- Analysis (1), Trade & Policy (1), Semiconductors (1)
China limits biotech platform exports as MOFCOM targets cell therapy
The Ministry of Commerce bans overseas ownership transfers of cell and gene therapy platforms while preserving contract…
Commerce exempts South Korean biopharma from import tariffs on Sept. 29
New BIS rules grant zero-tariff entry for antibody-drug conjugates and cell therapies from 19 allied jurisdictions, shielding…